Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that the latest information on its in-house discovered and developed eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN^?, ¡°eribulin¡±) will be presented during the 42nd San Antonio Breast Cancer Symposium (SABCS2019). The symposium will be held from December 10 through 14, 2019, in San Antonio, Texas in the United States.

A total of five poster presentations will be given at this year¡¯s SABCS including the study results evaluating absolute lymphocyte count at the baseline with eribulin as a predictor of overall survival from the post-hoc analysis of two Phase III clinical studies of eribulin in patients with advanced or metastatic breast cancer.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

Major poster presentations at SABCS2019:

Product, Poster No.	Title and scheduled presentation date (local time: Central Standard Time)
Eribulin Poster no.: P2-15-13	A Time-and-Motion Study of Chemotherapy Administration in Metastatic Breast Cancer December 12 (Thu), 7:00-9:00AM
Eribulin Poster no.: P4-10-08	Absolute lymphocyte count (ALC) is a predictor of eribulin benefit in advanced or metastatic breast cancer (MBC) December 13 (Fri), 7:00-9:00AM
Eribulin Poster no.: P5-05-03	Eribulin treatment activates type 1 IFNs to promote a gene expression signature associated with antitumor immunity December 13 (Fri), 5:00-7:00PM
Eribulin Poster no.: P6-07-02	Evaluating the effects of eribulin and paclitaxel on exosome formation and release from triple negative breast cancer cells December 14 (Sat), 7:00-9:00AM
Eribulin Poster no.: OT2-09-01	A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT study) December 12 (Thu), 5:00-7:00PM

?

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120